NEXT-GENERATION ANTIOXIDANTS: SHOULD WE TARGET PEROXIREDOXINS?

Area of Science:

• Biochemistry and Molecular Biology
• Redox Biology
• Pharmacology

Background:

• Reactive oxygen species (ROS) have dual roles in cell signaling and oxidative damage.
• Classical antioxidants fail clinically due to lack of specificity and disruption of redox balance.
• Peroxiredoxins (Prx) are specific thiol-dependent enzymes involved in redox signaling.

Purpose of the Study:

• To review the structural and functional aspects of Peroxiredoxins (Prx).
• To examine the roles of Prx in diseases such as cancer, neurodegeneration, and cardiovascular conditions.
• To evaluate Prx-targeted therapies as a superior strategy in redox medicine.

Main Methods:

• Literature review of Peroxiredoxin (Prx) structure and function.
• Analysis of Prx involvement in various disease pathologies.
• Survey of current and emerging pharmacological modulators of Prx.
• Evaluation of Prx-targeted therapy efficacy and challenges.

Main Results:

• Peroxiredoxins (Prx) exhibit enzymatic specificity and compartmentalization, crucial for precise redox signaling.
• Prx play context-dependent roles in cancer, neurodegeneration, and cardiovascular diseases.
• A growing number of pharmacological agents targeting Prx are under development.

Conclusions:

• Peroxiredoxin (Prx)-targeted therapy offers a more specific and potentially superior approach compared to traditional antioxidants.
• Prx represent a viable and promising strategy for future redox medicine applications.
• Further research into Prx modulators is warranted for therapeutic development.